Se connecter Inscription gratuite

NeuroVive Pharmaceutical AB Ret. sur les actifs

Quel est le Ret. sur les actifs de NeuroVive Pharmaceutical AB?

Le Ret. sur les actifs de NeuroVive Pharmaceutical AB est -36.94%

Quelle est la définition de Ret. sur les actifs?



Le rendement des actifs indique dans quelle mesure les actifs d'une entreprise génèrent des revenus. Il est calculé en divisant le résultat net par l'actif total moyen.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. sur les actifs des entreprises dans Miscellaneous secteur sur LSE par rapport à NeuroVive Pharmaceutical AB

Que fait NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Entreprises avec ret. sur les actifs similaire à NeuroVive Pharmaceutical AB